Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-06

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Cellular immunity is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is split out from the phagocytes membranes after phagocytosis. To investigators knowledge, this is the first study in literature to investigate maternal blood concentrations of presepsin in preeclampsia and healthy pregnant women.

Methods: The investigators examined maternal plasma interleukin-6, presepsin and pentraxin-3 concentrations in pregnant women with (n=44) and without L-PrE (n=44). These three inflammatory markers concentrations measured using enzyme-linked immunosorbent assays were compared.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

NCT05924061

Pre-Eclampsia Cathepsin B Level Pentraxin 3 Level

COMPLETED

Prostasin Levels in Preeclamptic Women

NCT06623942

Pre-Eclampsia

COMPLETED

Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2

NCT04239352

Pre-Eclampsia

COMPLETED

Maternal Serum Markers Predicting Preeclampsia At Early Gestations

NCT05131282

Pre-eclampsia Preterm Birth

COMPLETED

the Implications of Pathogenesis of Pre-Eclampsia

NCT00154934

Preeclampsia

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational case-control study was designed at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018 and January 2019. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2018/393). The study strictly adhered to the principles of the Declaration of Helsinki. All subjects included in the study gave oral and written informed consent. Eighty-eight women were enrolled in the study in two groups. All participants will gave their oral and written informed consent before their inclusion in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

late-onset preeclampsia

The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure \<110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.

interleukin-6, presepsin and pentraxin-3

Intervention Type OTHER

measurements and compare

Control

The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.

interleukin-6, presepsin and pentraxin-3

Intervention Type OTHER

measurements and compare

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interleukin-6, presepsin and pentraxin-3

measurements and compare

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* preeclampsia healthy pregnancy

Exclusion Criteria

1. pregnant women with any systemic condition (such as chronic hypertension, inflammatory and rheumatic diseases),
2. using any kind of medication throughout pregnancy (such as acetylsalicylic acid, corticosteroids or heparin),
3. pregnant women who had fever at the time of the first admission,
4. concurrent infections (urinary tract infection, cervicitis, etc.),
5. pregnancies complicated with premature membrane rupture or chorioamnionitis,
6. history of medication for PE treatment at the time of the first admission,
7. patients who had fetal congenital abnormalities or genetic syndromes,
8. drug user,
9. multiple gestations,
10. active labor.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes